Sanofi, Re­gen­eron say Dupix­ent suc­ceeds in an­oth­er late-stage COPD study, set­ting up fil­ing for FDA ap­proval

The megablock­buster an­ti-in­flam­ma­to­ry drug Dupix­ent suc­ceed­ed in a sec­ond late-stage COPD tri­al, Sanofi and Re­gen­eron said Mon­day, as the two drug­mak­ers plan to file for ap­proval by year’s end.

The com­mon lung dis­ease would be a ma­jor new mar­ket for Dupix­ent, a bi­o­log­ic first ap­proved in 2017 that has grown in­to one of the in­dus­try’s best-sell­ing drugs by treat­ing a range of in­flam­ma­to­ry con­di­tions such as atopic der­mati­tis and asth­ma. The topline re­sults from the NO­TUS tri­al fol­low pre­vi­ous suc­cess of the Phase III BORE­AS study an­nounced in March.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.